Waters’ Q3 Revenues Up 9.5 Percent in Q3 Despite Flat Rx Sales; MS Does ‘Very Well’ | GenomeWeb
Pharmaceutical sales continued to be a “mixed bag,” Waters’ chief executive said this week as the company reported a 9.5-percent uptick in sales for the third quarter, which swelled to $386.3 million from $352.6 million during the year-ago period.
During the three months ended Sept. 27, Waters also saw its profits increase 34.2 percent to $71.5 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.